Alpine Immune Sciences, Inc. (ALPN)

64,60 0,00 (0,00%) Alla chiusura: 04:00PM EDT

Alpine Immune Sciences, Inc.

188 East Blaine Street
Suite 200
Seattle, WA 98102
United States
206 788 4545
https://www.alpineimmunesciences.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 142

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Mitchell H. Gold M.D.	Executive Chairman & CEO	1,02M	N/D	1968
Dr. Stanford Peng M.D., Ph.D.	President and Head of Research & Development	940,1k	N/D	1971
Mr. Paul Rickey	Senior VP, CFO, Treasurer & Secretary	691,1k	N/D	1979
Mr. Ulrich Martin Fuhs	VP of Finance & Chief Accounting Officer	N/D	N/D	1968
Ms. M. Christina Yi	Chief Technology Officer	N/D	N/D	1976
Ms. Michelle Greenblatt	Director of Investor Relations & Corporate Communications	N/D	N/D	N/D
Dr. Remy Durand Ph.D.	Chief Business Officer	N/D	N/D	1986
Dr. Andrew Seth Sandler M.D.	Chief Medical Officer	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Governance aziendale

L'ISS Governance QualityScore di Alpine Immune Sciences, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.